|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1992; 19:1323-1334 © 1992 by the American College of Cardiology Foundation |
Department of Medicine, New England Medical Center, Boston, Massachusetts.
The implantable cardioverter-defibrillator (ICD) greatly reduces the incidence of sudden cardiac death among patients with recurrent sustained ventricular tachycardia and fibrillation who do not respond to conventional antiarrhythmic therapy. A cost-effectiveness analysis was performed, comparing the ICD, amiodarone and conventional agents. Actual variable costs of hospitalization and follow-up care were used for 21 ICD- and 43 amiodarone-treated patients. Life expectancy and total variable costs were predicted with use of a Markov decision analytic model. Clinical event rates and probabilities were based on published reports or expert opinion. Life expectancy with an ICD (6.1 years) was 50% greater than that associated with treatment with amiodarone (3.9 years) and 2.5 times that associated with conventional treatment (2.5 years). Assuming replacement every 24 months, ICD lifetime treatment costs (in 1989 dollars) for a 55-year old patient are expected to be $89,600 compared with $24,800 for amiodarone and $16,100 for conventional therapy, yielding a marginal cost/effectiveness ratio for ICD versus amiodarone therapy of 1f429,200/year of life saved, which is comparable to that of other accepted medical treatments. If technologic improvements extend average battery life to 36 months, the marginal cost/effectiveness ratio would be $21,800/year of life saved, and at 96 months it would be $13,800/year of life saved. Patient age at implantation did not significantly affect these results. If quality of life on amiodarone therapy is 30% lower than that with the ICD, the marginal cost/effectiveness ratio decreases by 35%. If the quality of life for patients receiving drugs is 40% lower than that of patients treated with an ICD, use of the defibrillator becomes the dominant strategy.
This article has been cited by other articles:
|
|
 |
|
  A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, M. A. Hlatky, and D. K. Owens Cost-Effectiveness of Implantable Cardioverter-Defibrillators N. Engl. J. Med., October 6, 2005; 353(14): 1471 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Al-Khatib, K. J. Anstrom, E. L. Eisenstein, E. D. Peterson, J. G. Jollis, D. B. Mark, Y. Li, C. M. O'Connor, L. K. Shaw, and R. M. Califf Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med, April 19, 2005; 142(8): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ezekowitz, P. W. Armstrong, and F. A. McAlister Implantable Cardioverter Defibrillators in Primary and Secondary Prevention: A Systematic Review of Randomized, Controlled Trials Ann Intern Med, March 18, 2003; 138(6): 445 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, M. A. Hlatky, N. R. Every, K. M. McDonald, P. A. Heidenreich, L. S. Parsons, and D. K. Owens Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction Ann Intern Med, November 20, 2001; 135(10): 870 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Boriani, M Biffi, C Martignani, M Gallina, and A Branzi Cost-effectiveness of implantable cardioverter-defibrillators Eur. Heart J., June 2, 2001; 22(12): 990 - 996. [PDF]
|
|
|
|
 |
|
 M. H. Gollob and J. J. Seger Current Status of the Implantable Cardioverter-Defibrillator Chest, April 1, 2001; 119(4): 1210 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Cheng, H. R. Rubin, N. R. Powe, N. K. Mellon, H. W. Francis, and J. K. Niparko Cost-Utility Analysis of the Cochlear Implant in Children JAMA, August 16, 2000; 284(7): 850 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.R. Roberts, T.R. Betts, and J.M. Morgan Cost effectiveness of the implantable cardioverter defibrillator Eur. Heart J., May 1, 2000; 21(9): 712 - 719. [PDF]
|
|
|
|
|
|
H. Calkins, J. T. Bigger Jr, S. J. Ackerman, S. B. Duff, D. Wilber, R. A. Kerr, M. Bar-Din, K. M. Beusterien, and M. J. Strauss Cost-Effectiveness of Catheter Ablation in Patients With Ventricular Tachycardia Circulation, January 25, 2000; 101(3): 280 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Wright and M. C. Weinstein Gains in Life Expectancy from Medical Interventions -- Standardizing Data on Outcomes N. Engl. J. Med., August 6, 1998; 339(6): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Mushlin, W. J. Hall, J. Zwanziger, E. Gajary, M. Andrews, R. Marron, K. H. Zou, and A. J. Moss The Cost-effectiveness of Automatic Implantable Cardiac Defibrillators: : Results From MADIT Circulation, June 2, 1998; 97(21): 2129 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Fahy, E. B. Sgarbossa, P. J. Tchou, and S. L. Pinski Hospital Readmission in Patients Treated With Tiered-Therapy Implantable Defibrillators Circulation, September 15, 1996; 94(6): 1350 - 1356. [Abstract] [Full Text]
|
|
|
|
|
|
G. Larsen, A. Hallstrom, J. McAnulty, S. Pinski, A. Olarte, S. Sullivan, M. Brodsky, J. Powell, C. Marchant, C. Jennings, et al. Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy Circulation, April 30, 2002; 105(17): 2049 - 2057. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
